The early success of Endologix Inc.'s Ovation endovascular abdominal aortic aneurysm (AAA) stent graft in the LUCY trial is a milestone for the ongoing effort by industry, researchers, and the FDA to better understand and address gender-specific challenges to cardiovascular device therapies.
LUCY study is a prospective non-randomized post-market registry designed to evaluate the low-profile (14 French) Ovation, which Endologix acquired in the 2016 deal for TriVascular Technologies Inc., specifically in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?